Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia
-
Published:2024-01-24
Issue:3
Volume:25
Page:1421
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Rodríguez-Medina Carlos1, Stuckey Ruth1ORCID, Bilbao-Sieyro Cristina12ORCID, Gómez-Casares María Teresa13ORCID
Affiliation:
1. Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain 2. Morphology Department, Universidad de Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain 3. Department of Medical Sciences, Universidad de Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain
Abstract
Recent progress in the use of massive sequencing technologies has greatly enhanced our understanding of acute myeloid leukemia (AML) pathology. This knowledge has in turn driven the development of targeted therapies, such as venetoclax, a BCL-2 inhibitor approved for use in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed adult patients with AML who are not eligible for intensive chemotherapy. However, a significant number of AML patients still face the challenge of disease relapse. In this review, we will explore biomarkers that may predict disease progression in patients receiving venetoclax-based therapy, considering both clinical factors and genetic changes. Despite the many advances, we conclude that the identification of molecular profiles for AML patients who will respond optimally to venetoclax therapy remains an unmet clinical need.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference101 articles.
1. Genomic classification and prognosis in acute myeloid leukemia;Papaemmanuil;N. Engl. J. Med.,2016 2. Gargallo, P., Molero, M., Bilbao, C., Stuckey, R., Carrillo-Cruz, E., Hermosín, L., Pérez-López, O., Jiménez-Velasco, A., Soria, E., and Lázaro, M. (2022). Next-Generation DNA Sequencing-Based Gene Panel for Diagnosis and Genetic Risk Stratification in Onco-Hematology. Cancers, 14. 3. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN;Wei;Blood,2022 4. Cancer Genome Atlas Research Network, Ley, T.J., Miller, C., Ding, L., Raphael, B.J., Mungall, A.J., Robertson, A., Hoadley, K., Triche, T.J., and Laird, P.W. (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med., 368, 2059–2074. 5. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms;Khoury;Leukemia,2022
|
|